Clinical value of fecal calprotectin

References

• Ng SC, Shi HY, Hamidi N, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–2778.
   PubMed Web of Science ®Google Scholar
• Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720–727.
   PubMed Web of Science ®Google Scholar
• Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019;156:1345–1353.e4.
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Bernstein CN, Bitton A, et al. Trends in epidemiology of pediatric inflammatory bowel disease in Canada: distributed network analysis of multiple population-based provincial health administrative databases. Am J Gastroenterol. 2017;112:1120–1134.
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361:2066–2078.
   PubMed Web of Science ®Google Scholar
• Birimberg-Schwartz L, Zucker DM, Akriv A, et al. Development and validation of diagnostic criteria for IBD subtypes including IBD-unclassified in children: a multicentre study from the pediatric IBD Porto group of ESPGHAN. J Crohns Colitis. 2017;11:1078–1084.
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel JF, Sands BE, et al. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn's disease. Aliment Pharmacol Ther. 2016;43:317–333.
   PubMed Web of Science ®Google Scholar
• Shah SC, Colombel JF, Sands BE, et al. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1245–1255.e8.
   PubMed Web of Science ®Google Scholar
• Froslie KF, Jahnsen J, Moum BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412–422.
   PubMed Web of Science ®Google Scholar
• Mosli MH, Zou G, Garg SK, et al. C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis. Am J Gastroenterol. 2015;110:802–819.
   PubMed Web of Science ®Google Scholar
• Holtman GA, Lisman-van Leeuwen Y, Reitsma JB, et al. Noninvasive tests for inflammatory bowel disease: a meta-analysis. Pediatrics. 2015;137:e20152126.
   Web of Science ®Google Scholar
• Moore BW. A soluble protein characteristic of the nervous system. Biochem Biophys Res Communs. 1965;19:739–744.
   PubMed Web of Science ®Google Scholar
• Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793–798.
   PubMed Web of Science ®Google Scholar
• Ayling RM, Kok K. Fecal calprotectin. Adv Clin Chem. 2018;87:161–190.
   PubMed Web of Science ®Google Scholar
• Nakashige TG, Zygiel EM, Drennan CL, et al. Nickel sequestration by the host-defense protein human calprotectin. J Am Chem Soc. 2017;139:8828–8836.
   PubMed Web of Science ®Google Scholar
• Zackular JP, Moore JL, Jordan AT, et al. Dietary zinc alters the microbiota and decreases resistance to Clostridium difficile infection. Nat Med. 2016;22:1330–1334.
   PubMed Web of Science ®Google Scholar
• Kehl-Fie Thomas E, Chitayat S, Hood MI, et al. Nutrient metal sequestration by calprotectin inhibits bacterial superoxide defense, enhancing neutrophil killing of staphylococcus aureus. Cell Host Microbe. 2011;10:158–164.
   PubMed Web of Science ®Google Scholar
• Vogl T, Tenbrock K, Ludwig S, et al. Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med. 2007;13:1042.
   PubMed Web of Science ®Google Scholar
• Tøn H, Brandsnes Ø, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292:41–54.
   PubMed Web of Science ®Google Scholar
• Manceau H, Chicha-Cattoir V, Puy H, et al. Fecal calprotectin in inflammatory bowel diseases: update and perspectives. Clin Chem Lab Med. 2017;55:474–483.
   PubMed Web of Science ®Google Scholar
• Hejl J, Theede K, Mollgren B, et al. Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Pract Lab Med. 2018;10:10–14.
   PubMedGoogle Scholar
• Heida A, Knol M, Kobold AM, et al. Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity. Clin Gastroenterol Hepatol. 2017;15:1742–1749.e2.
   PubMed Web of Science ®Google Scholar
• Oyaert M, Boel A, Jacobs J, et al. Analytical performance and diagnostic accuracy of six different faecal calprotectin assays in inflammatory bowel disease. Clin Chem Lab Med. 2017;55:1564–1573.
   PubMed Web of Science ®Google Scholar
• Labaere D, Smismans A, Van Olmen A, et al. Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J. 2014;2:30–37.
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, French J, Brookes MJ, et al. Between-assay variability of faecal calprotectin enzyme-linked immunosorbent assay kits. Ann Clin Biochem. 2013;50:53–61.
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Loof L, Merzoug RD, et al. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr. 2003;37:468–472.
   PubMed Web of Science ®Google Scholar
• Denson LA, Konikoff MR. Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis. 2006;12:524–534.
   PubMed Web of Science ®Google Scholar
• Poullis A, Foster R, Shetty A, et al. Bowel inflammation as measured by fecal calprotectin. Cancer Epidemiol Biomark Prev. 2004;13:279.
   PubMed Web of Science ®Google Scholar
• Joshi S, Lewis SJ, Creanor S, et al. Age-related faecal calprotectin, lactoferrin and tumour M2-PK concentrations in healthy volunteers. Ann Clin Biochem.
   Web of Science ®Google Scholar
• Walker WA. Gastrointestinal host defence: importance of gut closure in control of macromolecular transport. Ciba Found Symp. 1979;70:201–219.
   Google Scholar
• Cummins AG, Eglinton BA, Gonzalez A, et al. Immune activation during infancy in healthy humans. J Clin Immunol. 1994;14:107–115.
   PubMed Web of Science ®Google Scholar
• Kapel N, Campeotto F, Kalach N, et al. Faecal calprotectin in term and preterm neonates. J Pediatr Gastroenterol Nutr. 2010;51:542–547.
   PubMed Web of Science ®Google Scholar
• Li F, Ma J, Geng S, et al. Comparison of the different kinds of feeding on the level of fecal calprotectin. Early Hum Dev. 2014;90:471–475.
   PubMed Web of Science ®Google Scholar
• Savino F, Castagno E, Calabrese R, et al. High faecal calprotectin levels in healthy, exclusively breast-fed infants. Neonatology. 2010;97:299–304.
   PubMed Web of Science ®Google Scholar
• Ricos C, Cava F, Garcia-Lario JV, et al. The reference change value: a proposal to interpret laboratory reports in serial testing based on biological variation. Scand J Clin Lab Invest. 2004;64:175–184.
   PubMed Web of Science ®Google Scholar
• Padoan A, D’Incà R, Scapellato ML, et al. Improving IBD diagnosis and monitoring by understanding preanalytical, analytical and biological fecal calprotectin variability. Clin Chem Lab Med. 2018;56:1926–1935.
   PubMed Web of Science ®Google Scholar
• Dumoulin EN, Van Biervliet S, Langlois MR, et al. Proteolysis is a confounding factor in the interpretation of faecal calprotectin. Clin Chem Lab Med. 2015;53:65–71.
   PubMed Web of Science ®Google Scholar
• Haisma SM, van Rheenen PF, Wagenmakers L, et al. Calprotectin instability may lead to undertreatment in children with IBD. Arch Dis Childhood. 2019. DOI:10.1136/archdischild-2018-316584
   Google Scholar
• Lasson A, Stotzer PO, Ohman L, et al. The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis. J Crohns Colitis. 2015;9:26–32.
   PubMed Web of Science ®Google Scholar
• Oyaert M, Van den Bremt S, Boel A, et al. Do not forget about pre-analytics in faecal calprotectin measurement! Clin Chim Acta. 2017;473:124–126.
   PubMed Web of Science ®Google Scholar
• Reenaers C, Bossuyt P, Hindryckx P, et al. Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice. United European Gastroenterol J. 2018;6:1117–1125.
   PubMed Web of Science ®Google Scholar
• Moum B, Jahnsen J, Bernklev T. Fecal calprotectin variability in Crohn’s disease. Inflamm Bowel Dis. 2010;16:1091–1092.
   PubMed Web of Science ®Google Scholar
• Marín L, Cabré E, Domènech E, et al. High within-day variability of fecal calprotectin levels in patients with active ulcerative colitis: what is the best timing for stool sampling? Inflamm Bowel Dis. 2015;21:1072–1076.
   PubMed Web of Science ®Google Scholar
• Kristensen V, Malmstrøm GH, Skar V, et al. Clinical importance of faecal calprotectin variability in inflammatory bowel disease: intra-individual variability and standardisation of sampling procedure. Scand J Gastroenterol. 2016;51:548–555.
   PubMed Web of Science ®Google Scholar
• Bressler B, Panaccione R, Fedorak RN, et al. Clinicians’ guide to the use of fecal calprotectin to identify and monitor disease activity in inflammatory bowel disease. Can J Gastroenterol Hepatol. 2015;29:369–372.
   Web of Science ®Google Scholar
• Lundgren D, Eklof V, Palmqvist R, et al. Proton pump inhibitor use is associated with elevated faecal calprotectin levels. A cross-sectional study on subjects referred for colonoscopy. Scand J Gastroenterol. 2019;54:152–157.
   PubMed Web of Science ®Google Scholar
• Tibble J, Sigthorsson G, Foster R, et al. Faecal calprotectin and faecal occult blood tests in the diagnosis of colorectal carcinoma and adenoma. Gut. 2001;49:402.
   PubMed Web of Science ®Google Scholar
• Vavricka SR, Heinrich H, Buetikofer S, et al. The Vampire study: significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterol J. 2018;6:1007–1014.
   PubMed Web of Science ®Google Scholar
• Wang L, Mannalithara A, Singh G, et al. Low rates of gastrointestinal and non-gastrointestinal complications for screening or surveillance colonoscopies in a population-based study. Gastroenterology. 2018;154:540–555.e8.
   PubMed Web of Science ®Google Scholar
• Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS. Am J Gastroenterol. 2015;110:444–454.
   PubMed Web of Science ®Google Scholar
• Walker GJ, Moore L, Heerasing N, et al. Faecal calprotectin effectively excludes inflammatory bowel disease in 789 symptomatic young adults with/without alarm symptoms: a prospective UK primary care cohort study. Aliment Pharmacol Ther. 2018;47:1103–1116.
   PubMed Web of Science ®Google Scholar
• Holtman GA, Lisman-van Leeuwen Y, Day AS, et al. Use of laboratory markers in addition to symptoms for diagnosis of inflammatory bowel disease in children: a meta-analysis of individual patient data. JAMA Pediatr. 2017;171:984–991.
   PubMed Web of Science ®Google Scholar
• Koulaouzidis A, Douglas S, Rogers MA, et al. Fecal calprotectin: a selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy. Scand J Gastroenterol. 2011;46:561–566.
   PubMed Web of Science ®Google Scholar
• Lin JF, Chen JM, Zuo JH, et al. Meta-analysis: fecal calprotectin for assessment of inflammatory bowel disease activity. Inflamm Bowel Dis. 2014;20:1407–1415.
   PubMed Web of Science ®Google Scholar
• Rokkas T, Portincasa P, Koutroubakis IE. Fecal calprotectin in assessing inflammatory bowel disease endoscopic activity: a diagnostic accuracy meta-analysis. J Gastrointestin Liver Dis. 2018;27:299–306.
   PubMed Web of Science ®Google Scholar
• Zittan E, Kelly OB, Kirsch R, et al. Low fecal calprotectin correlates with histological remission and mucosal healing in ulcerative colitis and colonic Crohn’s disease. Inflamm Bowel Dis. 2016;22:623–630.
   PubMed Web of Science ®Google Scholar
• Goutorbe F, Goutte M, Minet-Quinard R, et al. Endoscopic factors influencing fecal calprotectin value in Crohn’s disease. J Crohns Colitis. 2015;9:1113–1119.
   PubMed Web of Science ®Google Scholar
• Zittan E, Kelly OB, Gralnek IM, et al. Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn’s disease activity. JGH Open. 2018;2:201–206.
   PubMed Web of Science ®Google Scholar
• Matsuura R, Watanabe O, Nakamura M, et al. Fecal calprotectin reflects endoscopic activity in patients with small-bowel Crohn’s disease according to double-balloon endoscopy findings. Nagoya J Med Sci. 2018;80:257–266.
   PubMed Web of Science ®Google Scholar
• Simon EG, Wardle R, Thi AA, et al. Does fecal calprotectin equally and accurately measure disease activity in small bowel and large bowel Crohn’s disease? – a systematic review. Intest Res. 2019;17:160–170.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
   PubMed Web of Science ®Google Scholar
• Kucharski M, Karczewski J, Mańkowska-Wierzbicka D, et al. Usefulness of endoscopic indices in determination of disease activity in patients with Crohn’s disease. Gastroenterol Res Pract. 2016;2016:1.
   Google Scholar
• Carman N, Tomalty D, Church PC, et al. Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn’s disease. Gastrointest Endosc. 2019;89:364–372.
   PubMed Web of Science ®Google Scholar
• Travis SP, Schnell D, Krzeski P, et al. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology. 2013;145:987–995.
   PubMed Web of Science ®Google Scholar
• Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest Endosc. 2004;60:505–512.
   PubMed Web of Science ®Google Scholar
• Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn’s disease: a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989;30:983–989.
   PubMed Web of Science ®Google Scholar
• Nakar I, Focht G, Church P, et al. Associations among mucosal and transmural healing and fecal level of calprotectin in children with Crohn’s disease. Clin Gastroenterol Hepatol. 2018;16:1089–1097.e4.
   PubMed Web of Science ®Google Scholar
• Mak WY, Buisson A, Andersen MJ Jr, et al. Fecal calprotectin in assessing endoscopic and histological remission in patients with ulcerative colitis. Dig Dis Sci. 2018;63:1294–1301.
   PubMed Web of Science ®Google Scholar
• Kristensen V, Roseth A, Ahmad T, et al. Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis. Gastroenterol Res Pract. 2017;2017:1.
   Google Scholar
• Kostas A, Siakavellas SI, Kosmidis C, et al. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease. World J Gastroenterol. 2017;23:7387–7396.
   PubMed Web of Science ®Google Scholar
• Takashima S, Kato J, Hiraoka S, et al. Evaluation of mucosal healing in ulcerative colitis by fecal calprotectin vs. fecal immunochemical test. Am J Gastroenterol. 2015;110:873.
   PubMed Web of Science ®Google Scholar
• Lee SH, Kim MJ, Chang K, et al. Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis. BMC Gastroenterol. 2017;17:110.
   PubMed Web of Science ®Google Scholar
• Calafat M, Lobaton T, Hernandez-Gallego A, et al. Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission. Dig Liver Dis. 2017;49:1327–1331.
   PubMedGoogle Scholar
• Carlsen K, Riis LB, Elsberg H, et al. The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis. Scand J Gastroenterol. 2018;53:825–830.
   PubMed Web of Science ®Google Scholar
• Theede K, Holck S, Ibsen P, et al. Fecal calprotectin predicts relapse and histological mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2016;22:1042–1048.
   PubMed Web of Science ®Google Scholar
• Walsh A, Kormilitzin A, Hinds C, et al. Defining faecal calprotectin thresholds as a surrogate for endoscopic and histological disease activity in ulcerative colitis – a prospective analysis. J Crohns Colitis. 2018;13:424–430.
   Web of Science ®Google Scholar
• Jones GR, Fasci-Spurio F, Kennedy NA, et al. Faecal calprotectin and MRI enterography in ileal Crohn’s disease: correlations between disease activity and long term follow up. J Crohns Colitis. 2018;13:442–450.
   Web of Science ®Google Scholar
• Turner D, Ruemmele FM, Orlanski-Meyer E, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care-an evidence-based guideline from European Crohn’s and colitis organization and European society of paediatric gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr. 2018;67:257–291.
   PubMed Web of Science ®Google Scholar
• Monteiro S, Dias de Castro F, Leite S, et al. Low fecal calprotectin predicts clinical remission in Crohn’s disease patients: the simple answer to a challenging question. Scand J Gastroenterol. 2019;54:49–54.
   PubMed Web of Science ®Google Scholar
• D’Arcangelo G, Oliva S, Dilillo A, et al. Predictors of long-term clinical and endoscopic remission in children with Crohn’s disease treated with infliximab. J Pediatr Gastroenterol Nutr. 2019;68(6):841–846.
   PubMedGoogle Scholar
• Yamamoto T, Shimoyama T, Umegae S, et al. Endoscopic score vs. fecal biomarkers for predicting relapse in patients with ulcerative colitis after clinical remission and mucosal healing. Clin Trans Gastroenterol. 2018;9:136.
   PubMed Web of Science ®Google Scholar
• Heida A, Park KT, van Rheenen PF. Clinical utility of fecal calprotectin monitoring in asymptomatic patients with inflammatory bowel disease: a systematic review and practical guide. Inflamm Bowel Dis. 2017;23:894–902.
   PubMed Web of Science ®Google Scholar
• Galgut BJ, Lemberg DA, Day AS, et al. The value of fecal markers in predicting relapse in inflammatory bowel diseases. Front Pediatr. 2017;5:292.
   PubMed Web of Science ®Google Scholar
• Musci JO, Cornish JS, Dabritz J. Utility of surrogate markers for the prediction of relapses in inflammatory bowel diseases. J Gastroenterol. 2016;51:531–547.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Shiraki M, Bamba T, et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis. 2014;29:485–491.
   PubMed Web of Science ®Google Scholar
• Garcia-Sanchez V, Iglesias-Flores E, Gonzalez R, et al. Does fecal calprotectin predict relapse in patients with Crohn’s disease and ulcerative colitis? J Crohns Colitis. 2010;4:144–152.
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15–22.
   PubMed Web of Science ®Google Scholar
• Wright EK, Kamm MA, De Cruz P, et al. Measurement of fecal calprotectin improves monitoring and detection of recurrence of Crohn's disease after surgery. Gastroenterology. 2015;148:938–947.e1.
   PubMed Web of Science ®Google Scholar
• Tham YS, Yung DE, Fay S, et al. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn's disease: systematic review and meta-analysis. Therap Adv Gastroenterol. 2018;11:175628481878557.
   Web of Science ®Google Scholar
• Qiu Y, Mao R, Chen BL, et al. Fecal calprotectin for evaluating postoperative recurrence of Crohn’s disease: a meta-analysis of prospective studies. Inflamm Bowel Dis. 2015;21:315–322.
   PubMed Web of Science ®Google Scholar
• Liu R, Guo Z, Cao L, et al. Profile of consecutive fecal calprotectin levels in the perioperative period and its predictive capacity for early endoscopic recurrence in Crohn’s disease. Dis Colon Rectum. 2018;62:318–326.
   Web of Science ®Google Scholar
• Louis E, Mary JY, Vernier-Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology. 2012;142:63–70.e5.
   PubMed Web of Science ®Google Scholar
• Buisson A, Mak WY, Andersen MJ, Jr, et al. Faecal calprotectin is a very reliable tool to predict and monitor the risk of relapse after therapeutic de-escalation in patients with inflammatory bowel diseases. J Crohns Colitis. 2019. DOI:10.1093/ecco-jcc/jjz023
   Google Scholar
• Colombel JF, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390:2779–2789.
   PubMedGoogle Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and Ileo-anal pouch disorders. J Crohns Colitis. 2017;11:649–670.
   PubMed Web of Science ®Google Scholar
• Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr. 2002;34:323–324.
   PubMed Web of Science ®Google Scholar
• Nissen AC, van Gils CE, Menheere PP, et al. Fecal calprotectin in healthy term and preterm infants. J Pediatr Gastroenterol Nutr. 2004;38:107–108.
   PubMed Web of Science ®Google Scholar
• Campeotto F, Butel MJ, Kalach N, et al. High faecal calprotectin concentrations in newborn infants. Arch Dis Childhood. 2004;89:F353.
   PubMed Web of Science ®Google Scholar
• Baldassarre ME, Altomare MA, Fanelli M, et al. Does calprotectin represent a regulatory factor in host defense or a drug target in inflammatory disease? Emiddt. 2007;7:1–5.
   Google Scholar
• Hestvik E, Tumwine JK, Tylleskar T, et al. Faecal calprotectin concentrations in apparently healthy children aged 0–12 years in urban Kampala, Uganda: a community-based survey. BMC Pediatr. 2011;11:9.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Li F, Wang J, et al. Fecal calprotectin in healthy children aged 1–4 years. PLoS One. 2016;11:e0150725.
   PubMed Web of Science ®Google Scholar
• Davidson F, Lock RJ. Paediatric reference ranges for faecal calprotectin: a UK study. Ann Clin Biochem. 2017;54:214–218.
   PubMed Web of Science ®Google Scholar
• Bressler B, Marshall JK, Bernstein CN, et al. Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. Gastroenterology. 2015;148:1035–1058.e3.
   PubMed Web of Science ®Google Scholar
• van Rheenen PF, Van de Vijver E, Fidler V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ. 2010;341:c3369.
   PubMed Web of Science ®Google Scholar